Erytech Pharma SA (EPA: ERYP) has appointed Alex Dusek as vice president of commercial strategy and member of the executive team, the biopharmaceutical company disclosed on Monday.
Dusek has 25 years of market access, product marketing and sales experience across small biotech start-ups and multi-national pharmaceutical companies.
Before joining Erytech, Dusek served as vice president of commercial strategy at Argos Therapeutics (OTCMKTS: ARGS). There he was responsible for pre-launch planning for the commercial distribution of an advanced cell therapy product.
His previous roles included leading global brand strategy at Bayer HealthCare Pharmaceuticals (ETR: BAYN) for the launch of a first-in-class, rare-disease agent, Adempas (riociguat). He was also United Therapeutics' (NASDAQ: UTHR) first marketing employee, building the company's marketing infrastructure and growing the pulmonary hypertension franchise.
Dusek will be based in the US, joining Erytech's expanding team in Cambridge, Massachusetts.
GenSight Biologics reports first patient treated in GS010 REVISE study
Biophytis secures Asian partnership and investment to advance Phase 3 sarcopenia programme
OncoHost receives BIG Innovation Award in Health category
MemorialCare hospitals recognised in 2026 Women's Choice Awards
Champions Oncology expands bioanalytical services with new technology and leadership
PhaseV receives three industry honours for AI in clinical development
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Revelation Pharma acquires Acacia Apothecary & Wellness
Viatris receives fifth consecutive recognition on Forbes' annual list of World's Best Employers
INOVIO announces inducement grant to new employee
AbbVie's Allergan Aesthetics announces Natrelle supplier agreement with Vizient